Most patients walk into the GLP-1 conversation with two questions in mind: can I get it, and how much does it cost. Both matter. But there are nine other questions that determine whether you'll actually tolerate the drug, stay on it long enough to see results, and avoid the contraindications that send some patients to the ER. Here's the field-tested checklist most patients don't think to ask — and what the right answers sound like.
Eligibility and cost are the obvious questions. The less-obvious-but-more-important ones are about safety history, side-effect management, dose titration, what happens if you can't tolerate it, and what happens when you stop. Most patients don't ask these until they're already on the drug and something's gone wrong.
The right doctor's answers should be specific, not vague. "We'll figure it out" is not a plan. "If you're nauseated past week 3, we drop you to 0.5mg for an extra cycle, and if it doesn't resolve by week 8 we consider switching to tirzepatide" is a plan. Specificity tells you whether your prescriber has actually titrated dozens of patients on this class — or is reading the package insert in real time.
A real GLP-1 conversation goes faster and lands better if you arrive with two things in hand. Skip these and most of the appointment time gets spent gathering information you already had.
Specifically: your family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), any personal history of pancreatitis or gallbladder issues, current medications (especially insulin or sulfonylureas if you're diabetic), pregnancy plans within the next 12 months, and your weight trend over the last year. These are the things that change the prescriber's calculus most.
Know whether your plan covers GLP-1s for your indication (T2D vs obesity vs OSA vs CV indication), what the prior authorization requirements are, and whether your plan has a step-therapy rule (must try cheaper drugs first). Most insurance plans publish this in their formulary documents. If your doctor doesn't know your plan's specifics, that's the first thing that needs to get figured out — it determines half the path forward.
Each one matters. Each one has a specific kind of answer that tells you whether your prescriber is doing thoughtful medicine or just writing prescriptions.
A few specific signals that the prescriber isn't a real partner for the GLP-1 journey — regardless of what their marketing says:
1. "Whatever your insurance covers." Without considering your medical history, contraindications, or what you're treating.
2. "Just follow the package insert." If they're not adapting the titration to you, they're not titrating — they're publishing.
3. "We can get you compounded if insurance denies." In 2026, this is the prior-shortage-exception loophole that's mostly no longer legitimate.
4. "You'll be fine." If they can't tell you which side effects are normal vs. ER-worthy, they haven't titrated enough patients.
5. "Come back if something goes wrong." No scheduled follow-up plan means no plan.
6. "We have an in-house pharmacy that handles everything." Vertical-integration arrangements can be legitimate, but they should be disclosed and you should be able to fill the script elsewhere if you want.
If you only remember three things from this article, remember these three categories of question — and ask one from each:
Those three questions, asked clearly and with the documents in hand to support them, separate the appointments that go well from the ones where you walk out unclear about what you're doing or why.
Clinical practice guidelines, FDA labels, and the trial data underlying current titration practice.
The full side-by-side comparison of Tirzepatide vs Semaglutide vs Retatrutide — trial data, side effects, cost, and which one fits which goal.
Open the GLP-1 comparison